logo BDSP

Base documentaire

  1. The treatment of depression with paroxetine in psychiatric practice in Germany : The possibilities and current limitations of drug monitoring.

    Article - En anglais

    A drug monitoring of the antidepressant paroxetine was carried out in Germany from August1992 to November 1993.

    The principal aim of this study was to collect demographic, diagnostic, efficacy, and medical-safety data regarding patients who were treated for up to 12 weeks with this SSRI.

    A secondary goal was the investigation of differences between patients who left treatment after 6 weeks or earlier and those who continued treatment.

    Evaluable data were obtained from 507 psychiatrists for 2817 patients, 1301 of whom extended treatment beyond 6 weeks. 64% of the patients had been pretreated for the current episode of depression. 50% were considered by their doctors to have either chronic or recurrent illness and 92% to possess moderate to severe symptomatology.

    Concomitant psychotropic medication was reported in 43% of cases, the most frequent medications being benzodiazepines, neuroleptics, and/or tricyclic antidepressants.

    Clear or complete improvement was noted for 63% of assessable patients by the end of week 6 and for 79% of the patients who extended treatment to 12 weeks.

    There were significantly more patients with DSM major depression and severe symptoms in the treatment-extender than in the 6-week treatment group.

    Paroxetine was tolerated well by most patients : of the 1009 adverse events reported, only 17 were considered « serious ».

    There were no suicides or cases of overdose attributable to paroxetine. (...)

    Mots-clés Pascal : Etat dépressif, Trouble humeur, Chimiothérapie, Paroxétine, Inhibiteur recapture, Sérotonine, Psychotrope, Surveillance biologique, Etude longitudinale, Facteur risque, Démographie, Efficacité traitement, Association médicamenteuse, Homme, Pipéridine dérivé

    Mots-clés Pascal anglais : Depression, Mood disorder, Chemotherapy, Paroxetine, Reuptake inhibitor, Serotonin, Psychotropic, Biological monitoring, Follow up study, Risk factor, Demography, Treatment efficiency, Drug combination, Human, Piperidine derivatives

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0120564

    Code Inist : 002B02B02. Création : 21/05/1997.